Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -37.82% is 630% below its 5-year average of -5.18%, near the low end of its 5-year range (-73.24%–64.11%).
As of the fiscal period ended Tuesday, June 30, 2026. 30.34% above its 12-month average of -54.29%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -37.82%.
RETURN ON EQUITY (ROE)
-37.82%
RETURN ON EQUITY (ROE) AVG TTM
-54.29%
RETURN ON EQUITY (ROE) AVG 3Y
-43.43%
RETURN ON EQUITY (ROE) AVG 5Y
-5.18%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+30.34%
CURRENT VS 3Y AVG
+12.92%
CURRENT VS 5Y AVG
-630.02%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+9.98%
vs the sector median at left
Maravai LifeSciences Holdings, Inc.
Market Cap
$2.21B
Return on Equity (ROE)
-37.82%
TTM Avg
-54.29%
3Y Avg
-43.43%
5Y Avg
-5.18%
Market Cap
$2.16B
Return on Equity (ROE)
-57.96%
TTM Avg
-57.45%
3Y Avg
-48.08%
5Y Avg
-40.68%
Market Cap
$2.29B
Return on Equity (ROE)
18.14%
TTM Avg
20.16%
3Y Avg
28.24%
5Y Avg
15.58%
Market Cap
$2.13B
Return on Equity (ROE)
-43.55%
TTM Avg
-14.07%
3Y Avg
-80.41%
5Y Avg
-980.81%
Market Cap
$2.13B
Return on Equity (ROE)
-23.58%
TTM Avg
-182.08%
3Y Avg
-186.85%
5Y Avg
-151.51%
Market Cap
$2.31B
Return on Equity (ROE)
N/A
TTM Avg
9.38%
3Y Avg
9.38%
5Y Avg
9.38%
Market Cap
$2.11B
Return on Equity (ROE)
9.17%
TTM Avg
8.21%
3Y Avg
8.13%
5Y Avg
7.80%
Market Cap
$2.33B
Return on Equity (ROE)
15.63%
TTM Avg
16.66%
3Y Avg
16.66%
5Y Avg
13.72%
Market Cap
$2.09B
Return on Equity (ROE)
-98.56%
TTM Avg
-37.96%
3Y Avg
-71.53%
5Y Avg
-45.53%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Maravai LifeSciences Holdings, Inc. (MRVI) | $2.21B | -37.82% | -54.29% | -43.43% | -5.18% |
| Pharvaris N.V. (PHVS)vs › | $2.16B | -57.96% | -57.45% | -48.08% | -40.68% |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.29B | 18.14% | 20.16% | 28.24% | 15.58% |
| GeneDx Holdings Corp. (WGS)vs › | $2.13B | -43.55% | -14.07% | -80.41% | -980.81% |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.13B | -23.58% | -182.08% | -186.85% | -151.51% |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.31B | N/A | 9.38% | 9.38% | 9.38% |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 9.17% | 8.21% | 8.13% | 7.80% |
| UFP Technologies, Inc. (UFPT)vs › | $2.33B | 15.63% | 16.66% | 16.66% | 13.72% |
| Vera Therapeutics, Inc. (VERA)vs › | $2.09B | -98.56% | -37.96% | -71.53% | -45.53% |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.35B | -84.78% | -42.91% | -54.25% | -44.36% |
ROE
-37.8%
ROA
-12.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -37.82% |
| 2026-03-31 | -49.42% |
| 2025-12-31 | -61.58% |
| 2025-09-30 | -49.40% |
| 2025-06-30 | -73.24% |
| 2025-03-31 | -54.13% |
| 2024-12-31 | -44.53% |
| 2024-09-30 | -65.09% |
| 2024-06-30 | -30.23% |
| 2024-03-31 | -31.91% |
| 2023-12-31 | -28.56% |
| 2023-09-30 | 4.73% |
| 2023-06-30 | 14.50% |
| 2023-03-31 | 29.39% |
| 2022-12-31 | 40.39% |
| 2022-09-30 | 47.25% |
| 2022-06-30 | 54.21% |
| 2022-03-31 | 58.92% |
| 2021-12-31 | 57.57% |
| 2021-09-30 | 46.04% |
| 2021-06-30 | 64.11% |
| 2021-03-31 | 66.94% |
| 2020-12-31 | 85.49% |
